News | Melanoma Institute Australia
For all media enquiries please email us on [email protected]
melanoma.org.auHere are some of the most recent melanoma updates from reputable sources:
-
Immunotherapy advances and news in 2025–2026 continue to emphasize adjuvant and neoadjuvant strategies, with several trials reporting favorable pathological responses and durable immune-related outcomes in high-risk melanoma patients. These developments are highlighted by melanoma-focused organizations and research groups, including trials of anti-PD-1/PD-L1 combinations (e.g., nivolumab, pembrolizumab) and related regimens. [Sources: The Melanoma Nursing Initiative updates; CureMelanoma blog and Melanoma Institute Australia coverage]
-
Neoadjuvant immunotherapy is increasingly regarded as a frontier in melanoma treatment, with new clinical trial results and reviews published in 2025–2026 showing potential benefits in resectable and high-risk scenarios, alongside discussions on optimal sequencing with surgery. [Sources: Melanoma Institute Australia news; CureMelanoma blog; Nature Medicine-related discussions summarized by melanoma news outlets]
-
Research into personalized and targeted approaches—such as cancer vaccines in combination with checkpoint inhibitors, tumor organoid platforms for modeling heterogeneity, and biomarker-driven trials—continues to surface, aiming to improve response rates and manage resistance in advanced melanoma. [Sources: Cancer Commons melanoma updates; CureMelanoma blog; Melanoma News coverage]
-
Major melanoma advocacy and research funding organizations are reporting increased investments in global melanoma research, patient education, and experiences, including initiatives around TIL therapy, acral melanoma, and biomarker testing. [Sources: CureMelanoma blog; Melanoma Research Alliance communications; Melanoma Institute Australia coverage]
If you’d like, I can:
- Narrow to a specific region (e.g., United States) or hospital system to pull the latest local updates.
- Compile a short, citation-rich brief with the top 5 most impactful 2025–2026 melanoma findings and trial results.
- Create a quick chart or bullet-point timeline of neoadjuvant vs adjuvant immunotherapy milestones in melanoma over the past 2 years.